Zheng ZH, Yang SQ. Metformin combined with mirtazapine for treatment of anorexia nervosa with dyspepsia: Clinical effect and impact on serum levels of norepinephrine, 5-hydroxy tryptamine and dopamine.
Shijie Huaren Xiaohua Zazhi 2014;
22:3699-3704. [DOI:
10.11569/wcjd.v22.i24.3699]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To explore the clinical effect of metformin combined with mirtazapine in the treatment of anorexia nervosa (AN) with dyspepsia.
METHODS: One hundred AN patients with dyspepsia treated at our hospital were randomly divided into either an observation group or a control group (n = 50 for each group). The control group was treated with mirtazapine tablets, and the observation group was additionally given oral metformin on the basis of mirtazapine tablets. Gastric juice pH was compared between before and after treatment and between the two groups. After 2, 6, and 12 wk of treatment, body weight changes, Hamilton depression scale (HAMD) score, and Hamilton anxiety scale (HAMA) score were compared between the two groups. Serum norepinephrine (NE), 5-hydroxy tryptamine (5-HT), dopamine (DA) and blood glucose levels were also compared.
RESULTS: Gastric juice pH increased significantly after treatment in both groups, and the increase was more significant in the observation group (t = 5.658, P < 0.05). After 2, 6, and 12 wk of treatment, body weight significantly increased in both groups compared with before treatment. After 6 and 12 wk of treatment, body weight was significantly lower in the observation group than in the control group (t = 4.805, 4.864, P < 0.05). After treatment, HAMA and HAMD scores decreased significantly, serum NE, 5-HT and DA levels significantly increased in both groups compared with before treatment (t = 3.784, 4.315, 4.783, P < 0.05). After treatment, fasting plasma glucose (FPG), glycated haemoglobin (HbAlc), and 2-h plasma glucose (2 h PG) tended to decrease in the observation group compared with before treatment and the control group, but the differences were not statistically significant (P > 0.05). TESS score and the incidence of adverse reactions showed no significant differences between the two groups (P > 0.05).
CONCLUSION: Metformin combined with mirtazapine can improve depressive symptoms and appetite in the treatment of AN, without obvious weight gain or hypoglycemia symptoms.
Collapse